


ABSTRACT OF THE DISCLOSURE

5       The invention relates to the use of derivatives of F-type prostaglandins as ocular hypotensives. The PGF derivatives used in accordance with the invention are represented by the following formula I:



15     wherein wavy line attachments indicate either the alpha ( $\alpha$ ) or beta ( $\beta$ ) configuration; dashed bonds represent a double bond, or a single bond, R is a substituted heteroaryl radical, R<sup>1</sup> is hydrogen or a lower alkyl radical having up to six carbon atoms, X is selected from the group consisting of -OR<sup>1</sup>, -N(R<sup>1</sup>)<sub>2</sub>, R<sup>1</sup> is hydrogen or a lower alkyl radical having up to six carbon atoms, X is selected from the group consisting of -OR<sup>1</sup>, -N(R<sup>1</sup>)<sub>2</sub> and -N(R<sup>5</sup>)SO<sub>2</sub>R<sup>6</sup>, wherein R<sup>5</sup> represents hydrogen or CH<sub>2</sub>OR<sup>6</sup> and R<sup>6</sup> represents hydrogen or a lower alkyl radical having up to six carbon atoms and halogen substituted derivatives of said lower alkyl radical, e.g. a fluoro substituted lower alkyl radical; Y is =O or represents 2 hydrogen radicals. Certain of the compounds represented by Formula I comprise another aspect of the present invention.